'Columbia University Libraries/Information Services'
Doi
Abstract
At present time, there is uncertainty regarding whether influenza-like illness in healthy adults is best managed by preventive efforts that use the trivalent influenza vaccine, administration of neuraminidase inhibitors at the onset of illness, or recommendation of supportive care alone at the onset of illness. We conducted a cost-effectiveness analysis that examined these 3 strategies for managing influenza-like illness. Vaccination with inactivated trivalent vaccine would save approximately 25perpersonwhileresultinginanetgainof∼3.2quality−adjustedhoursrelativetoprovidingtreatmentwiththeneuraminidaseinhibitoroseltamivir.Aquality−adjustedhourisafractionofaquality−adjustedlife−year,whichistheequivalentof1yearlivedinperfecthealth.Treatmentwithoseltamivirwasassociatedwithanincrementalcost−effectivenessofapproximately27,619 per quality-adjusted life-year gained relative to providing supportive care. Vaccination is cost-saving relative to providing either treatment with oseltamivir or providing supportive care alone